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a  b  s  t  r  a  c  t
Zostavax® is a live,  attenuated  varicella  zoster  virus  (VZV)  vaccine  developed  speciﬁcally  for  the  preven-
tion  of  HZ  and  PHN  in  individuals  aged  ≥50  years.  During  the  clinical  development  of  Zostavax,  which  was
mainly  in the  US,  the vaccine  was  administrated  by  the  subcutaneous  (SC)  route.  In  Europe,  many  health-
care  professionals  prefer  administering  vaccines  by  the intramuscular  (IM)  route.  This  was  an  open-label,
randomised  trial conducted  in  354  subjects  aged  ≥50  years.  The  primary  objectives  were  to  demonstrate
that  IM  administration  is  both  non-inferior  to SC  administration  in  terms  of  4-week  post-vaccination  geo-
metric  mean  titres  (GMTs),  and  elicits  an acceptable  geometric  mean  fold-rise  (GMFR)  of  antibody  titres
measured  by glycoprotein  enzyme-linked  immunosorbent  assay.  Pre-speciﬁed  non-inferiority  was  set  as
the  lower  bound  of  the  95%  conﬁdence  interval  (CI) of  the  GMT  ratio (IM/SC)  being >0.67.  An acceptable
GMFR  for the  IM route  was  pre-speciﬁed  as the lower  bound  of its  95% CI  being  >1.4. Description  of  the
VZV  immune  response  using the  interferon-gamma  enzyme-linked  immunospot  (IFN-  ELISPOT)  assay
and of  the  safety  were  secondary  objectives.
Participants  were  randomised  to IM or SC  administration  (1:1).  The  baseline  demographics  were
comparable  between  groups;  mean  age:  62.6  years  (range:  50.0–90.5).  The  primary  immunogenicity
objectives  were  met  (per  protocol  analysis):  GMT ratio  (IM/SC):  1.05  (95%  CI: 0.93–1.18);  GMFR:  2.7
(2.4–3.0).  VZV  immune  response  using  IFN-  ELISPOT  were  comparable  between  groups.  Frequencies
of  systemic  adverse  events  were  comparable  between  groups.  Injection-site  reactions  were  less  fre-
quent  with  IM  than  SC  route:  erythema  (15.9%  versus  52.5%),  pain  (25.6%  versus  39.5%)  and  swelling
(13.6%  versus  37.3%),  respectively.  In adults  aged  ≥50  years,  IM administration  of Zostavax  elicited  sim-
ilar  immune  responses  to SC  administration  and  was  well  tolerated,  with  fewer injection-site  reactions
than  with  SC  administration.
ublis©  2014  The  Authors.  P
. IntroductionHerpes zoster (HZ), commonly known as shingles, results from
he reactivation of varicella zoster virus (VZV), which remains
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latent in the spinal ganglia and cranial sensory ganglia after pri-
mary VZV infection. The primary infection is seen as varicella
or chickenpox [1–3]. HZ is characterised by a unilateral, painful,
vesicular rash that is usually limited to a single dermatome
[4].
In Europe, almost everybody is at risk of HZ, since more than 95%
of adults aged ≥40 years are VZV seropositive following varicella
and 90% of individuals become VZV seropositive before adolescence
[5,6]. There is a sharp increase in the incidence of HZ at the age of 50,
with 2/3 of HZ cases occurring in adults aged ≥50 [7]. The lifetime
risk of zoster is estimated to be 10–30% with incidence increasing
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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ith age, affecting up to 50% of people who live up to 85 years
7–10].
The most frequent and debilitating complication of HZ is post-
erpetic neuralgia (PHN), a neuropathic pain syndrome that can
ersist for months, years or even decades after the HZ rash has
one [11,12]. The frequency and severity of PHN increases with
ge, occurring in between 25% and 50% of patients with HZ aged
50 years old [13–16]. Although the mechanisms responsible for
aintaining VZV in its latent state and for its reactivation are not
ully understood, evidence suggests that cell-mediated immunity
CMI) is critical [17–19]. The age-related decline in VZV-speciﬁc
MI  has been shown to have temporal association with an increase
n the incidence and severity of HZ and its complications in older
dults [20–25].
HZ and particularly PHN are debilitating and have a damaging
mpact on multiple aspects of patients’ lives. They also have an
mpact on their physical functionality by interfering with activities
f daily living [26–32].
Zostavax® (commercialised in Europe by Sanoﬁ Pasteur MSD,
anufactured by Merck Sharpe and Dohme) is a live, attenuated
ZV vaccine developed speciﬁcally for the prevention of HZ and
HN in individuals aged ≥50 years [33]. The vaccine boosts VZV-
peciﬁc cell-mediated immunity (CMI); this boosted CMI  controls
eactivation of the latent VZV and/or replication and, therefore,
revents herpes zoster or attenuates its severity [17,34–39].
In the large-scale Shingles Prevention Study (SPS) involving
ore than 38,000 subjects aged ≥60 years, vaccine efﬁcacy for
he prevention of HZ was 63.9% (95% conﬁdence interval (CI):
5.5–70.9) in individuals aged 60–69 years, and 37.6% (95% CI:
5.0–48.1) in those aged ≥70 years [40,41]. The vaccine efﬁcacy for
he reduction in PHN was 65.7% (95% CI: 20.4–86.7) in those aged
0–69 years and 66.8% (95% CI: 43.3–81.3) for those aged ≥70 years.
ostavax has also been shown to reduce the burden of HZ-related
nterference with daily living activities and the impact on health-
elated quality of life [42]. In the Zostavax Efﬁcacy and Safety Trial
ZEST), involving more than 20,000 subjects aged 50–59 years, the
accine signiﬁcantly reduced the risk of developing HZ by 69.8%
95% CI: 54.1–80.6) [43]. In Europe, Zostavax is indicated for the
revention of HZ and PHN in adults aged ≥50 years [44].
During clinical development, which was mainly done in the
S, the vaccine was administered by the subcutaneous (SC) route.
he preference for the administration route can vary between
ealthcare professionals and between countries; in some European
ountries the preferred administration route is intramuscular (IM).
he objectives of this trial were to compare the immunogenic-
ty, safety and tolerability of Zostavax when administered by the
M route versus the SC route, to support and facilitate the use of
he vaccine in Europe by offering the choice for the administration
oute.
. Methods
.1. Study population
Healthy adults aged ≥50 years with a history of varicella or res-
dent for >30 years in a country with endemic VZV infection were
ligible. Subjects were excluded if they had previously been vac-
inated with any VZV-containing vaccine or had previously been
iagnosed with HZ. In addition, were excluded: any subjects with a
istory of a febrile episode (≥38.3 ◦C) in the 72 h prior to study vac-
ination, those who had received any live vaccine within 28 days
f study vaccination or inactivated vaccine within 14 days of study
accination or immunoglobulins or other blood products within 5
onths before vaccination and those who were taking systemic
ntiviral therapy or had an immune deﬁciency associated withne 33 (2015) 789–795
disease (e.g. human immunodeﬁciency virus, cancer) or medical
treatment (e.g. chemotherapy, transplant recipients).
The study was carried out in accordance with the principles of
Good Clinical Practice and the ethical principles of the Declaration
of Helsinki. The study protocol was  approved by the appropri-
ate institutional review boards and regulatory agencies. Written,
informed consent was obtained from all subjects before study
entry.
ClinicalTrials.gov identiﬁer: NCT01391546 and EudraCT identi-
ﬁer: 2009-012458-19.
2.2. Study design
This was an open-label, randomised, comparative, study con-
ducted in seven centres in Germany and three in Spain from June
2011 to September 2012 to compare IM and SC administration of
one dose of Zostavax in adults aged ≥50 years. The subjects were
randomised using an electronic case report form (e-CRF). Alloca-
tion schedules were generated using a 1:1 ratio with permuted
blocks of 4–6. The randomisation was  stratiﬁed by ‘ELISPOT’ site
(see below) or not and by age with three strata: 50–59, 60–69 and
≥70 years (because the immune response has been shown to be
age-dependent) [34,45,46]. There were no protocol amendments
after the start of subject recruitment.
Blood samples were taken at visit 1, before vaccination, and at
visit 2, 4 weeks after vaccination (between 28 and 35 days). The
humoral immune response was  assessed using the glycoprotein
enzyme-linked immunosorbent assay (gpELISA) assay to measure
the VZV antibody titre in all subjects and the CMI  response was
assessed for a sub-set of subjects enrolled at designated sites,
the ‘ELISPOT’ sites, using the interferon-gamma (IFN-)-enzyme-
linked immunospot (ELISPOT) assay [47,48].
Between visit 1 and 2, the participants were given a diary card
to record their temperature if they were febrile (oral tempera-
ture ≥38.3 ◦C), occurrence of any solicited injection-site (erythema,
swelling and pain) adverse reactions (Days 0–4) and any unsolicited
injection-site adverse reactions, varicella, varicella-like rashes, HZ
and zoster-like rashes and other systemic adverse events (AEs)
(Days 0–28). They were also asked to report any serious AEs (SAEs)
that occurred at any time during the study.
2.3. Study vaccine
The study vaccine, Zostavax, was  administered in the deltoid
region of the upper arm, by IM (needle: 25 mm,  23 gauge) or
SC (needle: 16 mm,  25 gauge) according to the randomisation.
Use of an anaesthetic cream or patch was  not allowed. Each
dose of 0.65 mL  contained ≥19,400 PFU of varicella-zoster virus,
Oka/Merck strain (live, attenuated) (Lot Numbers: WL00040507;
WL00046785).
2.4. Objectives
2.4.1. Co-primary objectives
The two co-primary objectives were to demonstrate that IM
administration of Zostavax in healthy adults aged ≥50 years is
non-inferior to SC administration in terms of the 4-week post-
vaccination VZV antibody geometric mean titre (GMT) measured
with gpELISA and that it induces an acceptable geometric mean
fold rise [GMFR] of VZV antibody titres (gpELISA) from pre- to 4-
week post-vaccination. Non-inferiority was deﬁned as the lower
bound of the two-sided 95% conﬁdence interval (CI) around the
post-vaccination GMT  ratio (IM group/SC group) being greater than
2/3 (i.e. ruling out a decrease of ≥1.5-fold). An acceptable GMFR
was deﬁned as the lower bound of the two-sided 95% CI around
the GMFR being greater than 1.4 in the IM group based on a
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Scree ned
N=359
(ELISPOT: N=228)
Randomised
N=354
(ELISPOT: N=228)
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Fig. 1. Disposition of study participants. IM:  intramuscular; SC: sub
inimum increase that was established using the results from
he SPS trial [41]. Success of the trial required that both of the
o-primary objectives were satisﬁed.
.4.2. Secondary objectives
The secondary immunological objectives were to describe the
pELISA GMT  and GMFR in both groups and the IFN- ELISPOT GMC
nd GMFR in both groups in the ELISPOT sub-set at 4-weeks post-
accination. The secondary safety objectives were to describe and
ompare the safety proﬁles of Zostavax administered by the IM and
C routes.
.5. Sample size calculation
It was planned to randomise 177 subjects to each group
N = 354). Assuming that 90% of the participants would be evaluable,
his sample size would give 159 evaluable subjects per group for
he main analysis (per protocol). If the true GMT  ratio (IM group/SC
roup) was 1.0 (with a standard deviation of 1.1 on a natural log
cale) and the true GMFR was 2.0 (with a standard deviation of 1.0
n a natural log scale), the study would have an overall power of
0% based on a 2.5% one-sided alpha-error rate.
Descriptive analyses were performed for the ELISPOT subgroup.
he number of the subjects to be enrolled in the subgroup was
ecided, based on previous experience, so that it would be possi-
le to provide a reliable estimate of the post-vaccination ELISPOT
MC [49]. The planned sample size was 80 evaluable subjects per
roup, giving 114 randomised subjects per group, assuming that
0% of the subjects would be evaluable for the ELISPOT per protocol
nalysis.accination
ous; BS: blood sample; PPS: per protocol set; FAS: full analysis set.
2.6. Statistics
SAS® (V9.1.3; SAS Institute Inc., Cary, North Carolina, USA) was
used to perform the statistical analyses. The immunogenicity anal-
yses were performed on the per protocol set (PPS) that included all
randomised participants who  received the study vaccine and had
at least one valid (either pre- or post-vaccination) immunogenicity
evaluation for VZV antibody (PPS) or VZV ELISPOT count (ELISPOT
PPS). The gpELISA GMT  ratio (IM group/SC group) and the corre-
sponding 95% CI were calculated using a longitudinal data analysis
model including pre- and post-vaccination log-transformed titres
as response variables and age at vaccination, group and visit (pre-
and post-vaccination) as covariates [50]. This model handles miss-
ing data and provides the same results as an ANCOVA model when
there are no subjects with missing data. The CI around the GMFR
in the IM group was  calculated using Student’s t distribution for
paired samples on log-transformed data.
The safety analyses were performed on all participants who
received the study vaccine and who  had safety follow-up (safety
analysis set). Data were analysed according to the administration
route actually used for the vaccine. Descriptive statistics and risk
differences between the IM and SC groups for the comparison of
the safety data are provided.
3. Results
3.1. Subject disposition and baseline characteristicsA total of 354 of the 359 screened subjects were randomised
to receive ZOSTAVAX by the IM route (N = 177; ELISPOT sub-
set N = 115) or SC route (N = 177; ELISPOT sub-set N = 113); 353
792 J. Diez-Domingo et al. / Vaccine 33 (2015) 789–795
Table  1
Demographic characteristics of subjects in the randomised set.
IM group (N = 177) SC group (N = 177) Total (N = 354)
Age at vaccination (years)a
Mean (±SD) 62.6 (±8.3) 62.6 (±8.5) 62.6 (±8.4)
Median (min; max) 61.1 (50.0; 90.5) 61.1 (50.1; 86.1) 61.1 (50.0; 90.5)
Age  group (years) n (%)
50–59 81 (45.8) 82 (46.3) 163 (46.0)
60–69 56 (31.6) 55 (31.1) 111 (31.4)
≥70  40 (22.6) 40 (22.6) 80 (22.6)
Gender n (%)
Male 79 (44.6) 80 (45.2) 159 (44.9)
Female 98 (55.4) 97 (54.8) 195 (55.1)
a Data missing for one subject in the IM group.
Table 2
Pre- and 4-week post-vaccination GMTs and GMFRs of VZV antibody titres (gpELISA units/mL; per protocol seta).
IM route group (N = 175) SC route group (N = 177)
n GMT  (95% CI) n GMT  (95% CI)
Pre-vaccination 175 144.6 (125.3–166.9) 176 158.9 (137.9–183.1)
Post-vaccination 168 395.3 (350.6–445.6) 173 391.7 (348.9–439.7)
IM  route group (N = 175) SC route group (N = 177)
n GMFR (95% CI) n GMFR (95% CI)
Post-/pre-vaccination 168 2.7 (2.4–3.0) 172 2.5 (2.2–2.8)
C tre; gpELISA, glycoprotein enzyme-linked immunosorbent assay; IM, intramuscular; N,
n ZV, varicella-zoster virus.
h at least one valid for pre- or post-vaccination immunogenicity evaluation.
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Fig. 2. Reverse cumulative distribution curve of VZV antibody titres pre-vaccination
and  4-week post vaccination with ZOSTAVAX (IM or SC route) measured by gpELISAI, conﬁdence interval; GMFR, geometric mean fold-rise; GMT, geometric mean ti
umber of subjects; n, number of subjects with available data; SC, subcutaneous; V
a The per protocol analysis set for the primary outcome included all subjects wit
ubjects received the study vaccine (Fig. 1). One randomised subject
n the IM group belonging to the ELISPOT subset was not vaccinated
ue to past history of herpes zoster, which was an exclusion criteria,
nd no blood sample was provided, thus the full analysis set (FAS)
nd the safety analysis set included 353 subjects (IM: n = 176; SC:
 = 177). In addition, in the IM group, one subject received immuno-
uppressive therapy prior to vaccination and during the trial. Thus
52 subjects (IM: n = 175; SC: n = 177) were included in the per
rotocol set (PPS). Four subjects were excluded from the ELISPOT
andomised sub-set: the subject with a past history of herpes zoster
nd three other subjects because there were no pre- and post-
accination ELISPOT results (due to loss of sample during transfer to
he laboratory for testing; IM:  n = 1; SC: n = 2); thus the ELISPOT FAS
ncluded 224 subjects (IM: n = 113; SC: n = 111). Two additional sub-
ects were excluded from the IM ELISPOT sub-set due to exposure
o VZV and rash of interest following vaccination; these protocol
eviations invalidated their post-vaccination ELISPOT results; thus
he ELISPOT PPS included 222 subjects (IM: n = 111; SC: n = 111).
The two groups were comparable in terms of age and gender
Table 1). The baseline characteristics for the ELISPOT randomised
ubset were comparable to those of the overall randomised
et.
.2. Immunogenicity
.2.1. Primary immunogenicity objectives
Both primary immunogenicity objectives were met. The 4-week
ost-vaccination VZV antibody GMT  in the IM group was  non-
nferior to that in the SC group (lower bound of the 95% CI of
he GMT  ratio (IM/SC) >0.67). The estimated GMT  ratio (IM/SC)
as 1.05 (95% CI: 0.93–1.18) (p < 0.001). In the IM group, the esti-
ated GMFR of the VZV antibody titres from pre-vaccination to
-week post-vaccination was 2.7 (95% CI: 2.4–3.0) which allowed
o conclude that it was acceptable (lower bound of the 95% CI >1.4)
Table 2).(per-protocol set). The solid lines show the results for the subjects in the IM group
and  the dashed lines show those for subjects in the SC group. IM:  intramuscular; SC:
subcutaneous; VZV: varicella-zoster virus.
3.2.2. Secondary immunogenicity objectives
The pre-vaccination and 4-week post-vaccination VZV antibody
GMTs and GMFRs were comparable between groups (Table 2 and
Fig. 2). There was  a trend for these values to decrease with increas-
ing age (Table 3). The pre-vaccination and 4-week post-vaccination
ELISPOT GMCs and the ELISPOT GMFR were comparable between
groups (Table 4).
3.3. SafetyFewer participants in the IM group experienced at least one
AE compared with those in the SC group (47.2% versus 69.5%,
respectively; Table 5). The rates of systemic AEs were compara-
ble between the administration routes (23.3% versus 22.6% for IM
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Table  3
Pre- and 4-week post-vaccination geometric mean titres (GMTs) and geometric mean fold-rises (GMFR; post/pre-vaccination) of VZV antibody titres (gpELISA units/mL) by
age  group – per protocol set.
IM group (N = 175) SC group (N = 177)
Pre-vaccination Post-vaccination Pre-vaccination Post-vaccination
50–59 years old
n 79 74 82 79
GMT  [95% CI] 133.9 [108.9;164.7] 446.1 [368.1;540.6] 164.8 [134.3;202.3] 454.1 [390.1;528.5]
GMFR [95% CI] 3.2 [2.7;3.9] 2.8 [2.3;3.4]
60–69  years old
n 56 55 54 54
GMT  [95% CI] 154.5 [117.4;203.3] 394.7 [321.1;485.2] 158.7 [121.4;207.4] 338.6 [273.1;419.8]
GMFR [95% CI] 2.5 [2.0;3.1] 2.2a [1.8;2.6]
≥70  years old
n 40 39 40 40
GMT  [95% CI] 153.4 [112.8;208.5] 314.8 [250.7;395.3] 147.7 [108.1;201.9] 356.3 [268.9;471.9]
GMFR [95% CI] 2.1 [1.8;2.5] 2.4 [1.9;3.0]
a Data for one subject missing: n = 53; CI, conﬁdence interval; VZV, varicella-zoster virus.
Table 4
Pre- and 4-week post-vaccination GMC  and GMFR of VZV INF-γ ELISPOT counts (ELISPOT per protocol set).
IM route group (N = 111) SC route group (N = 111)
na GMC (95% CI) na GMC  (95% CI)
Pre-vaccination 101 64.3 (49.6–83.4) 96 58.4 (42.6–80.2)
Post-vaccination 103 209.8 (175.2–251.3) 105 195.7 (161.9–236.6)
IM  route group (N = 111) SC route group (N = 111)
na GMFR (95% CI) na GMFR (95% CI)
Post-/pre-vaccination 93 3.3 (2.8–3.9) 90 3.4 (2.7–4.3)
CI, conﬁdence interval; GMC, geometric mean count; GMFR, geometric mean fold-rise; IM, intramuscular; INF, interferon; N, number of participants; n, number of participants
with  available data; SC, subcutaneous; VZV, varicella-zoster virus.
a Missing data for pre-vaccination time points are due to non-evaluable samples. Missing data for post-vaccination time points are due to protocol deviations and thus
results  were excluded from the per protocol analyses.
Table 5
Summary of safety (safety analysis set).
IM group (N = 176) SC group (N = 177)
n  (%) n (%)
AE (Days 0–28) 83 (47.2) 123 (69.5)
Vaccine-related AE (Days 0–28) 68 (38.6) 118 (66.7)
Injection site reaction (Days 0–28) 60 (34.1) 114 (64.4)
Solicited injection site reaction
(Days 0–4)
58 (33.0) 110 (62.1)
Unsolicited injection site
reaction (Days 0–28)
9 (5.1) 14 (7.9)
Systemic AE (Days 0–28) 41 (23.3) 40 (22.6)
Vaccine-related systemic AE
(Days 0–28)
12 (6.8) 13 (7.3)
Injection site rash (Days 0–28) 0 0
Non-injection site rash (Days 0–28) 1 (0.6) 0
SAE 1 (0.6) 2 (1.1)
Vaccine-related SAE 0 0
Withdrawal due to an AE 0 0
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Fig. 3. Percentage of subjects (and 95% CI) with injection site adverse reactions from
Days 0 to 28 (safety analysis set) for the IM group (N = 176; grey bars) and the SC
group (N = 177; white bars). The numbers above the bars are the percentage risk
differences between the IM and SC groups with their 95% conﬁdence intervals. p
values were calculated for the solicited adverse reactions only, in compliance withE, adverse event; IM,  intramuscular; N, number of participants; n (%), number (per-
entage) of participants presenting the AE at least once; SAE, serious adverse event;
C,  subcutaneous.
nd SC groups, respectively; Table 5). Injection-site reactions were
igniﬁcantly less frequent in the IM group than in the SC group
or: erythema (15.9% versus 52.5%; p < 0.001), pain (25.6% versus
9.5%; p = 0.005), swelling (13.6% versus 37.3%; p < 0.001) and pru-
itus (1.7% versus 6.2%), respectively (Fig. 3). One subject in the
M group reported a zoster-like rash (right thoracic dermatome) of
ild intensity that occurred 12 days post vaccination and lasted
 days. Although no specimen was obtained for VZV conﬁrmationthe  protocol; pruritus was an unsolicited adverse reaction and therefore no p value
was  calculated.
by PCR testing, the investigator considered the event to be possi-
bly related to the study vaccine. Three subjects experienced SAEs
(IM Group: obstructive hernia (n = 1); SC Group: humerus fracture
(n = 1), deep venous thrombosis (n = 1)), none of which were con-
sidered to be vaccine-related by the investigators (Table 5). None
of the subjects withdrew from the trial because of an AE.
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. Discussion
This study was designed to assess the immunogenicity and
afety of IM administration of Zostavax compared with SC adminis-
ration. The results show that the immune response to IM Zostavax
s similar to that to SC Zostavax. In addition, IM administration
esults in signiﬁcantly fewer injection-site reactions with a compa-
able rate of systemic AEs, as has been described for other vaccines
51,52].
The estimated GMFR, obtained using the gpELISA assay, was
omparable to those observed in previous studies that evaluated
mmune response at 4-week post-vaccination in adults aged ≥50
ears [34,45,46]. Unlike our trial, these three trials had only two
ge groups: 50–59 years and >60 years, therefore we could only
ompare the 50–59 age groups in which the values ranged from
.4 to 3.9. As expected and as already reported in other stud-
es, the estimated GMFRs were numerically higher in those aged
0–59 years (3.2 in the IM group and 2.8 in the SC group) com-
ared with those who were older (60–69 years: 2.5 and 2.2; ≥70
ears: 2.1 and 2.4, in the IM and SC groups, respectively). The
ower immunological response observed with age is due to the phe-
omenon of immunosenescence, or ageing of the immune system
53,54].
The estimated GMFRs obtained using the IFN- ELISPOT assay
n a subset of subjects (N = 228) enrolled at 4 of the 10 study sites
ere comparable between the two groups: 3.3 in IM group and 3.4
n SC group. The IFN- ELISPOT was used in two previous studies in
lder populations (≥60 years) [49,55]. In one of these studies, the
stimated GMFR was 2.1 at 6-weeks post-vaccination and 2.7 and
.1 at 2 and 6-weeks post-vaccination, respectively, in the other
tudy [49,55].
The safety proﬁle of Zostavax in the SC group was compara-
le to the known safety proﬁle of the product [56]. In the IM
roup, there were fewer injection-site reactions than in the SC
roup. Lower rates of injection-site reactions were also reported
n two studies in healthy children that compared the IM and
C administration of varicella vaccine, Varivax® and a combina-
ion paediatric vaccine, ProQuad®, which contain the same VZV
train [57,58]. A literature review of clinical trials reported that in
wo trials comparing immunogenicity or safety of pneumococcal
accines in adults and in four trials comparing immunogenic-
ty or safety of inﬂuenza vaccines administered via IM or SC
outes in adults, the immunogenicity and systemic safety were
t least as good by IM administration compared with SC, and
hat reactogenicity was generally better with IM administration
51].
One possible limitation of this study was the open-label design
or the routes of administration. However, randomisation was per-
ormed using an eCRF thus minimising any subject selection bias.
n addition, the immunogenicity assays were performed on blinded
amples so that the laboratory staff who performed the immuno-
enicity assays (including primary criteria) were unaware of the
accination administration route. The present study had an excel-
ent completion rate, with only two randomised subjects (2/354;
.6%) not completing the trial.
. Conclusion
In adults aged ≥50 years, IM administration of Zostavax elicited
imilar immune responses to SC administration and was  well
olerated with fewer injection-site reactions than with SC admin-
stration. These data support the administration of vaccine using
ither SC or IM and thus could allow healthcare professionals the
exibility to choose their preferred administration route in routine
linical practice.ne 33 (2015) 789–795
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